Aumed, a.s., Komořanská 326/63, 143 14 Praha - Modřany, Česká republika

+420 603 587 701 English


EN - foto 02

AUMED, a.s. launches its own self-sampling set based on the principle of gargling of the oral cavity and pharynx. The new sampling set was named PCR GARGLING KIT. The self-sampling device is intended for collecting samples, which are then tested in a professional laboratory for the presence of viruses infecting the oral cavity and upper respiratory tract. The kit was primarily developed for the detection of SARS-CoV-2 virus, which causes covid-19. The evaluation is performed in the laboratory by detection based on nucleic acid amplification such as RT-PCR and RT-LAMP methods. In the transport medium, viruses remain vital and can also be used for culture tests.

The kit is fully validated and meets CE IVD certification. The kit is registered by the State Institute for Drug Control (SÚKL) under registration number 00959967 (issued by SIDC-CZ).The sampling kit was developed and  manufactured by a Czech pharmaceutical company AUMED, a.s.. Company production capacity is up to 100,000 kits per day. The collection by gargling is of the same quality as the common collection from the nasopharynx, however, the collection by gargling is pleasant compared to the common collection from the nasopharynx and does not irritate the mucous membranes. Instead of pushing the sticks into the nose, it is enough to gargle a sip of ordinary water for 20-30 seconds and then empty this content from the mouth into the enclosed collection tube containing the transport powder. The user then closes the tube and packs it according to the instructions. The user will perform this procedure either at the sampling point or at home, from where he will then deliver the sample to the sampling point, to the laboratory or, for example, to his doctor.

The combination of the new sampling kit and the AUMED test RT-LAMP Assay SARS-CoV-2 test kit creates completely new possibilities for the detection of new coronavirus in the population. Painless and fast collection without queues will be followed by fast and reliable diagnostics!

If you are interested, contact us by email and we will contact you immediately with a price offer depending on the number of required sets.

You can find more information at or from the tab dedicated to this product.


AUMED, a.s. successfully completed the 1st stage of the project entitled “Transferfaktor TFI – Medicinal product”

29. 11. 2022

AUMED, a.s. successfully completed the 1st stage of the project entitled “Transferfaktor TFI – Medicinal product”, registration number CZ.01.1.02/0.0/0.0/20_318/0026008. As…

AUMED, a.s. presented phage research at the Phages 2022 conference in Oxford

26. 09. 2022

AUMED participated in the 12th annual bacteriophage conference in Oxford, which is the only European phage conference with such a…

AUMED a.s. founded a new company AUMED Immunology a.s.

19. 09. 2022

AUMED a.s. founded a new company AUMED Immunology a.s.. AUMED, a.s. is the sole shareholder of the newly formed company….

Research projects of Aumed, a.s. are financed by the European Structural Funds:
Research and development of a new pertussis vaccine
Transfer factor — research and development of a new medical form
Production of diagnostic kit for covid-19 on the lamp principle
TFI Transfer Factor – Medicine

and with financial support from the state budget through the Ministry of Industry and Trade in the TRIO program:
Research and development of a new oral administration of vaccine

European Union
European Regional Development Fund
OP Enterprise and Innovation for Competitiveness

Tel.: +420 603 587 701
Komořanská 326/63, 143 14 Praha - Modřany, Česká republika
(c) 2017, Aumed a.s